Hepatitis C News and Research

Latest Hepatitis C News and Research

Viewpoints: Nothing 'magical' about 6 million enrollees; the high cost of hep C medicine

Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate -- which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange -- is going to be pretty close to the mark.

29 Mar 2014

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working.

27 Mar 2014

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

Inovio Pharmaceuticals, Inc. today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

26 Mar 2014

HIV and Hepatitis C vaccines now closer to reality

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.

26 Mar 2014

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure - not just halt - the illness.

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Researchers develop mathematical model that provides insights about molecular mechanisms behind virus assembly

Mathematicians at the University of York have joined forces with experimentalists at the University of Leeds to take an important step in discovering how viruses make new copies of themselves during an infection.

25 Mar 2014

Democratic lawmakers ask hepatitis C drugmaker to justify price

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).

25 Mar 2014

Transgene raises €65.5M via two-step capital increase

Transgene SA, a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces that it has raised a total of €65.5 million via a two-step capital increase.

25 Mar 2014

First Edition: March 24, 2013

Today's early morning highlights from the major news organizations examine the final week for health law enrollment, the Supreme Court case this week about the law's contraceptive mandate and the fourth anniversary of the enactment of the controversial overhaul.

24 Mar 2014

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.

19 Mar 2014

Viewpoints: The lesson from Florida's special election; hospital deaths; costs of treating hep C

But in recent months, the political landscape has grown bleaker [for Democrats] .... The question, of course, is why so many Republicans turned out [in the Florida special election last week] and why so few Democrats did. The answer among strategists on both sides was: Obamacare. But not in the sense that the healthcare law is so unpopular that Democrats are doomed; in fact, as more people sign up for health coverage, polls suggest that Obamacare is a little less toxic now than it was last fall. Instead, the problem is that a high-decibel debate over Obamacare has the effect of prompting conservatives to come out and vote, but not liberals (Doyle McManus, 3/16).

18 Mar 2014

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.

18 Mar 2014

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

A rule of electoral politics is that when a Democratic wave is building, the media broadcast it like a foregone conclusion. When a Republican wave is building, Beltway pundits are the last to admit it. After Tuesday's GOP win in a Florida special House election, even the press corps now agrees that Republicans are poised for major gains in November, assuming the GOP has the wit to exploit it (3/12).

14 Mar 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Viewpoints: Nothing 'magical' about 6 million enrollees; the high cost of hep C medicine

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

HIV and Hepatitis C vaccines now closer to reality

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Researchers develop mathematical model that provides insights about molecular mechanisms behind virus assembly

Democratic lawmakers ask hepatitis C drugmaker to justify price

Transgene raises €65.5M via two-step capital increase

First Edition: March 24, 2013

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Viewpoints: The lesson from Florida's special election; hospital deaths; costs of treating hep C

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

Viewpoints: The impact of Florida's special election; drug testing for doctors; the toll from Alzheimer's

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

Hepatitis C drug fuels cost debate

First Edition: March 12, 2014

Parasites in human are most likely to interact via food source

Viewpoints: Exploiting botched exchanges; falling number of uninsured; Medicare drug plan retreat

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in